The efficacy of radiotherapy in the treatment of intraocular metastases

E. Minatel, M. G. Trovo, L. Forner, G. Franchin, A. De Paoli, M. Roncadin, C. Gobitti, G. Bassignano

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

From January 1980 to May 1991, 28 patients with intraocular metastases were seen at our Institute. Three presented with bilateral metastases and two developed contralateral involvement. Out of the 33 ocular metastases 27 were managed by radiotherapy. The most common primary tumour sites were breast (18/28 patients) and lung (3/28). 22 patients were treated with an 8 MV linear accelerator, using a 4 x 4 cm anterior direct field. The median dose was 40 Gy/20 fractions (range 28 Gy/14 fractions to 50 Gy/25 fractions). Of the 27 treatments reported, 16 resulted in a complete response (59%), six in a partial response (22%) and five resulted in no change (19%). Complete and partial responses lasted for a median time of 13 months (range of 3-89+ months). The median survival time from the start of ocular treatment was 13 months. The aim of radiation treatment is either to prevent or to postpone the visual loss caused by intraocular metastases.

Original languageEnglish
Pages (from-to)699-702
Number of pages4
JournalBritish Journal of Radiology
Volume66
Issue number788
Publication statusPublished - 1993

Fingerprint

Radiotherapy
Neoplasm Metastasis
Particle Accelerators
Therapeutics
Breast
Radiation
Lung
Survival
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Minatel, E., Trovo, M. G., Forner, L., Franchin, G., De Paoli, A., Roncadin, M., ... Bassignano, G. (1993). The efficacy of radiotherapy in the treatment of intraocular metastases. British Journal of Radiology, 66(788), 699-702.

The efficacy of radiotherapy in the treatment of intraocular metastases. / Minatel, E.; Trovo, M. G.; Forner, L.; Franchin, G.; De Paoli, A.; Roncadin, M.; Gobitti, C.; Bassignano, G.

In: British Journal of Radiology, Vol. 66, No. 788, 1993, p. 699-702.

Research output: Contribution to journalArticle

Minatel, E, Trovo, MG, Forner, L, Franchin, G, De Paoli, A, Roncadin, M, Gobitti, C & Bassignano, G 1993, 'The efficacy of radiotherapy in the treatment of intraocular metastases', British Journal of Radiology, vol. 66, no. 788, pp. 699-702.
Minatel, E. ; Trovo, M. G. ; Forner, L. ; Franchin, G. ; De Paoli, A. ; Roncadin, M. ; Gobitti, C. ; Bassignano, G. / The efficacy of radiotherapy in the treatment of intraocular metastases. In: British Journal of Radiology. 1993 ; Vol. 66, No. 788. pp. 699-702.
@article{8fad72b5864c4517ad81c9dd72616158,
title = "The efficacy of radiotherapy in the treatment of intraocular metastases",
abstract = "From January 1980 to May 1991, 28 patients with intraocular metastases were seen at our Institute. Three presented with bilateral metastases and two developed contralateral involvement. Out of the 33 ocular metastases 27 were managed by radiotherapy. The most common primary tumour sites were breast (18/28 patients) and lung (3/28). 22 patients were treated with an 8 MV linear accelerator, using a 4 x 4 cm anterior direct field. The median dose was 40 Gy/20 fractions (range 28 Gy/14 fractions to 50 Gy/25 fractions). Of the 27 treatments reported, 16 resulted in a complete response (59{\%}), six in a partial response (22{\%}) and five resulted in no change (19{\%}). Complete and partial responses lasted for a median time of 13 months (range of 3-89+ months). The median survival time from the start of ocular treatment was 13 months. The aim of radiation treatment is either to prevent or to postpone the visual loss caused by intraocular metastases.",
author = "E. Minatel and Trovo, {M. G.} and L. Forner and G. Franchin and {De Paoli}, A. and M. Roncadin and C. Gobitti and G. Bassignano",
year = "1993",
language = "English",
volume = "66",
pages = "699--702",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "788",

}

TY - JOUR

T1 - The efficacy of radiotherapy in the treatment of intraocular metastases

AU - Minatel, E.

AU - Trovo, M. G.

AU - Forner, L.

AU - Franchin, G.

AU - De Paoli, A.

AU - Roncadin, M.

AU - Gobitti, C.

AU - Bassignano, G.

PY - 1993

Y1 - 1993

N2 - From January 1980 to May 1991, 28 patients with intraocular metastases were seen at our Institute. Three presented with bilateral metastases and two developed contralateral involvement. Out of the 33 ocular metastases 27 were managed by radiotherapy. The most common primary tumour sites were breast (18/28 patients) and lung (3/28). 22 patients were treated with an 8 MV linear accelerator, using a 4 x 4 cm anterior direct field. The median dose was 40 Gy/20 fractions (range 28 Gy/14 fractions to 50 Gy/25 fractions). Of the 27 treatments reported, 16 resulted in a complete response (59%), six in a partial response (22%) and five resulted in no change (19%). Complete and partial responses lasted for a median time of 13 months (range of 3-89+ months). The median survival time from the start of ocular treatment was 13 months. The aim of radiation treatment is either to prevent or to postpone the visual loss caused by intraocular metastases.

AB - From January 1980 to May 1991, 28 patients with intraocular metastases were seen at our Institute. Three presented with bilateral metastases and two developed contralateral involvement. Out of the 33 ocular metastases 27 were managed by radiotherapy. The most common primary tumour sites were breast (18/28 patients) and lung (3/28). 22 patients were treated with an 8 MV linear accelerator, using a 4 x 4 cm anterior direct field. The median dose was 40 Gy/20 fractions (range 28 Gy/14 fractions to 50 Gy/25 fractions). Of the 27 treatments reported, 16 resulted in a complete response (59%), six in a partial response (22%) and five resulted in no change (19%). Complete and partial responses lasted for a median time of 13 months (range of 3-89+ months). The median survival time from the start of ocular treatment was 13 months. The aim of radiation treatment is either to prevent or to postpone the visual loss caused by intraocular metastases.

UR - http://www.scopus.com/inward/record.url?scp=0027216587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027216587&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 699

EP - 702

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 788

ER -